USZ BioResource COVID-19

Development of a SARS-CoV-2 Research Biobank and Databank

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04414657

Enrollment

150

Registered

2020-06-04

Start date

2020-04-09

Completion date

2021-09-30

Last updated

2022-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID19

Brief summary

Mono-centric. Blood sampling for biobank development, including linkage to patient data (resource for research on COVID19).

Interventions

OTHERblood sampling for biobank

blood sampling for biobank

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* m/f age \> 18 years * SARS-CoV-2 infektion (according to WHO guideline) * hospitalisation, general ward * acceptable language knowledge * voluntary IFC and biobank appendix

Exclusion criteria

* contra indication for blood sampling

Design outcomes

Primary

Measure	Time frame	Description
blood sampling for biobank	2 years	development of a biobank

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026